Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth

Ohuod Hawsawi1, Weinan Xue1, Tingting Du2

  • 1Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.

Cell Reports. Medicine
|January 10, 2025
PubMed

Insights

Mitochondrial uncouplers like nitazoxanide (NTZ) inhibit prostate cancer growth by blocking the E2F1 pathway. This FDA-approved drug disrupts energy production, offering a new therapeutic strategy for prostate cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer growth relies on ATP from oxidative phosphorylation (OXPHOS).
  • The E2F1 pathway is critical for prostate cancer progression.
  • Mitochondrial uncouplers disrupt cellular energy production.

Purpose of the Study:

  • To investigate the effect of mitochondrial uncouplers on E2F1-mediated pathways in prostate cancer.
  • To determine if nitazoxanide (NTZ) and its metabolite tizoxanide (TIZ) can inhibit prostate cancer cell growth.
  • To explore the underlying molecular mechanisms of NTZ/TIZ anti-cancer activity.

Main Methods:

  • Treatment of prostate cancer cells with NTZ/TIZ.
  • Analysis of gene expression related to cell cycle, DNA synthesis, and lipid synthesis.
  • Assessment of cell cycle arrest, DNA synthesis, and lipogenesis.
  • Investigation of the AMP-activated kinase (AMPK)-p38 signaling pathway.

Main Results:

  • NTZ/TIZ inhibited E2F1-mediated gene expression crucial for cell cycle and biosynthesis.
  • NTZ/TIZ induced G1 cell cycle arrest and impeded DNA synthesis and lipogenesis.
  • The anti-cancer effects of TIZ correlated with its OXPHOS-uncoupling activity.
  • NTZ/TIZ activated the AMPK-p38 pathway, leading to E2F1 inhibition.

Conclusions:

  • Mitochondrial uncoupling inhibits a key oncogenic pathway in prostate cancer.
  • NTZ/TIZ demonstrates anti-cancer activity by disrupting OXPHOS and inhibiting E2F1.
  • Repositioning NTZ and other mitochondrial uncouplers for prostate cancer therapy is supported.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K